Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
BioDrugs · 2024
DOI: 10.1007/s40259-024-00671-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDrugs, 2024. Verfasst von Krzysztof Selmaj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Center of Neurology, University of Warmia & Mazury, Olsztyn, Lodz, Poland. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hexal AG.
Abstract (Originalsprache)
A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired. Biosimilar natalizumab (PB006 [biosim-NTZ]; developed by Polpharma Biologics S.A. and marketed globally as Tyruko®; Sandoz) has been developed as a successor to reference natalizumab (Tysabri® [ref-NTZ]; Biogen) and is the first US Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biosimilar in neurology. As per the FDA and EMA indications for ref-NTZ, biosim-NTZ is approved to treat relapsing forms of multiple sclerosis (USA, EU) and Crohn's disease (USA only). Approval of biosim-NTZ was based on the 'totality of evidence', a comprehensive body of data collected during the development process, demonstrating similarity to its reference medicine. The foundational step of demonstrating structural and functional similarity between biosim-NTZ and ref-NTZ confirmed identical primary and indistinguishable higher order structures, as well as matching binding affinity to α4β1/α4β7 integrins. Following the confirmation of matching structure and function, pharmacokinetic/pharmacodynamic similarity of biosim-NTZ to ref-NTZ in healthy subjects was demonstrated, with no clinically meaningful differences identified in safety and immunogenicity. A comparative, double-blind, randomized study (Antelope) was also conducted in patients with relapsing-remitting multiple sclerosis and demonstrated matching efficacy, safety, and immunogenicity with no clinically meaningful differences between biosim-NTZ and ref-NTZ. This review presents the totality of evidence that confirmed the biosimilarity of biosimilar natalizumab to its reference medicine, which supported its approval by the FDA and the EMA. [Graphical plain language summary available].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Center of Neurology, University of Warmia & Mazury, Olsztyn, Lodz, Poland.
- Polpharma Biologics S.A., Gdansk, Poland.
- Staburo GmbH, Munich, Germany.
- Hexal AG (a Sandoz company), Holzkirchen, Germany.
- The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USA.
- Hexal AG (a Sandoz company), Holzkirchen, Germany. laura.jacobs@sandoz.com.
Förderung
- Hexal AG
Zitieren
APA
Selmaj, K., Roth, K., Höfler, J., Vitzithum, K., Derlacz, R., von Richter, O., Hornuss, C., Poetzl, J., Singer, B., & Jacobs, L. (2024). Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab. BioDrugs. https://doi.org/10.1007/s40259-024-00671-4
Vancouver
Selmaj K, Roth K, Höfler J, Vitzithum K, Derlacz R, von Richter O, et al. Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab. BioDrugs. 2024. doi:10.1007/s40259-024-00671-4
BibTeX
@article{Selmaj2024,
author = {Selmaj, Krzysztof and Roth, Karsten and Höfler, Josef and Vitzithum, Klaus and Derlacz, Rafał and von Richter, Oliver and Hornuss, Cyrill and Poetzl, Johann and Singer, Barry and Jacobs, Laura},
title = {Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab},
journal = {BioDrugs},
year = {2024},
doi = {10.1007/s40259-024-00671-4}
}
EUVIMED